Consumer-Driven Future of GLP-1s: Apps & Social Media
Explore how social media trends and digital health apps are transforming access to GLP-1 medications in Canada, moving beyond traditional healthcare channels.
Category : Search result: diabetes medications
Manitoba diabetes rate 'alarming', study finds
A new study reveals an alarming diabetes rate in Manitoba. Learn the key findings, regional disparities, and what this means for public health in the province.
Weight Watchers Unveils New Platform for GLP-1 Era
Weight Watchers launches a fully integrated digital platform offering comprehensive support for members using GLP-1 medications, featuring personalized nutrition, coaching, and community. Discover the future of weight management.
Faulty Glucose Monitors Recalled in Canada
Health Canada issues a recall for specific FreeStyle Libre 3 Plus sensors due to potential for incorrect glucose readings. Patients advised to check lot numbers immediately.
Manitoba urged to mandate insulin help for students with diabetes
Manitoba's official opposition calls for a mandatory standard of care for children with type-1 diabetes in schools. Parents in Winnipeg are advocating for provincial support for younger students.
Novo's obesity drug shows 14.5% weight loss in trial
Novo Nordisk's experimental obesity drug amycretin demonstrates significant weight loss results in mid-stage study, advancing to late-phase testing for diabetes patients.
Denmark compensates for Novo Nordisk vision loss
Danish authorities provide compensation to patients experiencing vision loss linked to Novo Nordisk medications. Learn about the pharmaceutical safety developments affecting Canadian consumers.
GLP-1 Drugs Changing Canadian Food Habits: Study
New research reveals how diabetes medications Ozempic and Wegovy are transforming Canadian shopping patterns and food consumption. Discover the surprising impacts.
Ozempic Penis: The Truth Behind Viral Claim
Discover the truth about 'Ozempic penis' - the viral claim about GLP-1 medications. Urologists explain why it's an optical illusion and reveal real sexual side effects.
Trump's Plan to Slash Obesity Drug Prices
Former President Donald Trump unveils ambitious strategy to dramatically reduce costs of groundbreaking weight-loss medications, promising relief for millions struggling with obesity.
Trump Obesity Drug Deal Boosts Pharma Stocks
Major pharmaceutical giants Novo Nordisk and Eli Lilly experience significant stock surges as former President Donald Trump considers a groundbreaking obesity drug partnership, potentially revolutionizing weight loss treatment accessibility.
Canada's inconsistent diabetes support in schools needs fix
Canadian provinces face a critical health equity gap as students with diabetes navigate inconsistent support systems in schools. Learn why national standards are urgently needed.
Eli Lilly's Weight Loss Drugs Spark Billion-Dollar Bidding War
Pharmaceutical giant Eli Lilly reports explosive growth driven by Mounjaro and Zepbound, creating intense investor competition and reshaping the obesity treatment landscape.
Weight-Loss Pill Race Revolutionizes Healthcare Market
Pharmaceutical giants and startups race to develop next-generation weight-loss treatments as demand soars and market valuations skyrocket in this healthcare revolution.
Night Light Exposure Linked to Major Health Risks
Groundbreaking research suggests that exposure to artificial light at night could significantly increase your risk of developing cardiovascular disease and diabetes.
Page 1 of 1